These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33771890)

  • 1. Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report.
    Esfahani K; Henderson Berg MH; Zargham H; Billick R; Pehr K; Redpath M; Roshdy O; Miller WH
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
    Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
    J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
    J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
    Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN
    JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
    Langan EA; Budner K; Zillikens D; Terheyden P
    Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab.
    Ogawa-Momohara M; Muro Y; Goto K; Obuse C; Satoh M; Kono M; Akiyama M
    J Dermatol; 2020 Jun; 47(6):e217-e219. PubMed ID: 32173880
    [No Abstract]   [Full Text] [Related]  

  • 8. Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.
    Martínez-Doménech Á; García-Legaz Martínez M; Magdaleno-Tapial J; Valenzuela-Oñate C; Pérez-Pastor G; Pérez-Ferriols A
    Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events.
    Chan L; Hwang SJE; Byth K; Kyaw M; Carlino MS; Chou S; Fernandez-Penas P
    J Am Acad Dermatol; 2020 Feb; 82(2):311-316. PubMed ID: 31233857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
    Hwang SJE; Fernández-Peñas P
    Curr Probl Dermatol; 2018; 53():82-92. PubMed ID: 29131040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
    Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
    Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
    Wagner NB; Lenders MM; Kühl K; Reinhardt L; André F; Dudda M; Ring N; Ebel C; Stäger R; Zellweger C; Lang R; Paar M; Gussek P; Richtig G; Stürmer SH; Kimeswenger S; Oellinger A; Forschner A; Leiter U; Weide B; Gassenmaier M; Schraag A; Klumpp B; Hoetzenecker W; Berking C; Richtig E; Ziemer M; Mangana J; Terheyden P; Loquai C; Nguyen VA; Gebhardt C; Meier F; Diem S; Cozzio A; Flatz L; Röcken M; Garbe C; Eigentler TK
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.
    Joseph RW; Cappel M; Goedjen B; Gordon M; Kirsch B; Gilstrap C; Bagaria S; Jambusaria-Pahlajani A
    Cancer Immunol Res; 2015 Jan; 3(1):18-22. PubMed ID: 25287118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
    J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resolution of pembrolizumab-associated lichenoid dermatitis with a single dose of methotrexate.
    Varma A; Friedlander P; De Moll EH; Desman G; Levitt J
    Dermatol Online J; 2020 May; 26(5):. PubMed ID: 32621697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.
    Harvey NT; Millward M; Macgregor K; Bucat RP; Wood BA
    Am J Dermatopathol; 2016 Dec; 38(12):e159-e162. PubMed ID: 27870733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.
    Hwang SJ; Carlos G; Chou S; Wakade D; Carlino MS; Fernandez-Penas P
    Melanoma Res; 2016 Aug; 26(4):413-6. PubMed ID: 27031539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare and fatal complication of immune checkpoint inhibition: a case report of haemophagocytic lymphohistiocytosis with severe lichenoid dermatitis.
    Choi S; Zhou M; Bahrani E; Martin BA; Ganjoo KN; Zaba LC
    Br J Haematol; 2021 Jun; 193(6):e44-e47. PubMed ID: 33954981
    [No Abstract]   [Full Text] [Related]  

  • 19. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
    Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
    J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K; McGettigan S; Elenitsas R; Chu EY
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.